DPP IV Inhibitors: Market Research Report
This report analyzes the worldwide markets for DPP-IV Inhibitors in US$ Million by the following drugs – Sitagliptin, Vildagliptin, Saxagliptin, and Other DPP-IV Inhibitors (including Linagliptin and Alogliptin among others). The report provides separate comprehensive analytics for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2008 through 2017. The report profiles 31 companies including many key and niche players such as Arisaph Pharmaceuticals, Inc., AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Eli Lilly And Company, Merck & Co, Inc., Mitsubishi Tanabe Pharma Corporation, Novartis AG, and Takeda Pharmaceutical Company Limited. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Contents
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONSStudy Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
2.INDUSTRY OVERVIEW
Market Outlook
Major Events in the DPP-IV Inhibitor Space
Current and Future Analysis
The Diabetic Epidemic
Type-2 Diabetes Treatment – A Brief Overview
Overview of Drug Classes in Anti-Diabetic Drugs Category
Rationale for Use of DPP-4 Inhibitors
Comparison of Anti-Diabetic Drug Classes by HbAC1 Reduction
DPP-4 Inhibitors – Complementing Existing Approaches
Outlook for DPP-IV Therapies Remains Robust
DPP-4 Inhibitors versus GLP-1 Receptor Agonists
Distinction Between GLP-1 Receptor Agonists and DPP-4 Inhibitors
Hunt for Novel Therapeutic Areas Attracts Pharma to DPP-4 Market
Limited Efficacy Drives Use of Combination Products
3.DPP-IV INHIBITORS - MARKET DYNAMICS
The DPP-4 Inhibitor Domain
Select Approved DPP-4 Inhibitors in Developed Markets
Januvia – The Leading DPP-IV Inhibitor Drug Worldwide
Huge Potential Exists for Januvia and Other DPP-4 Inhibitors
Januvia to Concede Market Share; Yet Remain the Market Leader
“Me-Too” Competition Fails to Halt Januvia’s Success
Galvus Sales Garner Significant Growth
A Comparison of Januvia and Galvus
Pharmacological Comparison of Sitagliptin and Vildagliptin
Anti-Diabetics Arena in a Quandary as Late Stage Development Drug Faces Trouble
Increasing Competition to Taper Opportunities for Pipeline Drugs
4.A REVIEW OF SELECT APPROVED DRUGS, AND PIPELINE ANALYSIS
Januvia® Franchise (Merck & Co.)
Table 1: Global Sales of Januvia (Sitagliptin) Franchise by Drug (2007-2010): Value Sales in US$ Million for Januvia and Janumet (includes corresponding Graph/Chart)
Table 2: Global Sales of Januvia by Region (2007-2010): Value Sales in US$ Million for US and Rest of World (includes corresponding Graph/Chart)
Table 3: Global Sales of Janumet by Region (2007-2010): Value Sales in US$ Million for US and Rest of World (includes corresponding Graph/Chart)
Galvus (Novartis)
Onglyza (Bristol-Myers Squibb and AstraZeneca)
Table 4: Global Sales of Onglyza (Saxagliptin) Franchise by Region (2009 & 2010): Value Sales in US$ Million for the US and Rest of World (includes corresponding Graph/Chart)
Tradjenta (Boehringer Ingelheim)
A Brief Comparison of Select Marketed Drugs
DPP-IV Inhibitor Pipeline
5.DIABETES INCIDENCE AND PREVALENCE
Table 5: Worldwide Prevalence of Diabetes Mellitus by Region: 2010 & 2030 (includes corresponding Graph/Chart)
Diabetes Mellitus Cases Worldwide – A Demographic Analysis by Geographic Region
North America
The United States
Canada
Mexico
Table 6: Prevalence of Diabetes Mellitus in North America (2010 & 2030): Breakdown by Country, Age Group, and Gender (In ‘000 People & %)
Europe
Table 7: Prevalence of Diabetes Mellitus in Europe (2010 & 2030): Breakdown by Country, Age Group, and Gender (In ‘000 People & %)
Asia-Pacific
Table 8: Prevalence of Diabetes Mellitus in South East Asia (2010 & 2030): Breakdown by Country, Age Group, and Gender (In ‘000 People & %)
Table 9: Prevalence of Diabetes Mellitus in Western Asia (2010 & 2030): Breakdown by Country, Age Group, and Gender (In ‘000 People & %)
South & Central America
Table 10: Prevalence of Diabetes Mellitus in South & Central America (2010 & 2030): Breakdown by Country, Age Group, and Gender (In ‘000 People & %)
Rest of World
Table 11: Prevalence of Diabetes Mellitus in Africa (2010 & 2030): Breakdown by Country, Age Group, and Gender (In ‘000 People & %)
Table 12: Prevalence of Diabetes Mellitus in The Middle East & North Africa (2010 & 2030): Breakdown by Country, Age Group, and Gender (In ‘000 People & %)
6.DPP-IV INHIBITORS – AN OVERVIEW OF THE DRUG CLASS
Physiology of Glucose Homeostasis
Glucose Homeostasis in the Fasting Stage
Glucose Homeostasis in the Fed Stage
What is DPP-4?
Introduction to DPP-4 Inhibitors
Mechanism of Action of DPP-4 Inhibitors
Schematic Representation of DPP-IV Inhibitor’ Mechanism of Action
DPP-4 Inhibitors in Combination with Other Anti-diabetic Medications
Advantages of DPP-4 Inhibitors
Type-2 Diabetes – The Most Prevalent Form of Diabetes
Bio-chemistry of T2DM
7.PRODUCT APPROVALS/INTRODUCTIONS
Boehringer, Eli Lilly Obtain European Marketing Authorization for Trajenta
Boehringer, Eli Lilly’s Tradjenta Receives FDA Approval
Bristol-Myers and AstraZeneca Launch Kombiglyze™ XR in the US
Bristol-Myers and AstraZeneca Obtain EU Approval for New Saxagliptin Label Update
Ono Pharmaceutical Obtains Additional Indication for Glactiv in Japan
Takeda Obtains Label Extension for Nesina in Japan
AstraZeneca and BMS Obtain FDA Approval for Kombiglyze™ XR
Novartis Obtains Approval for Vildagliptin in Japan
Ono and Banyu Launch Glactiv in Japan
Takeda Launches Nesina® in Japan
Merck, Sharp & Dohme Introduces Januvia in China
Ono and Banyu Receive Japanese Approval for Sitagliptin
AstraZeneca and Bristol-Myers Receive EU Marketing Authorization for Onglyza
AstraZeneca and Bristol-Myers Obtain FDA Clearance for Onglyza
Merck’s Janumet™ Receives EU Approval
MSD Pharmaceuticals Introduces Januvia in India
Merck Launches Januvia in New Zealand
Novartis Obtains EU Approval for Combination Diabetes Drug - Eucreas
Novartis’ Diabetes Drug – Galvus Receives EU Approval
MSD’s JANUVIA® Obtains EU Approval for Treatment of Type 2 Diabetes
Merck Obtains FDA Approval for Januvia
8.RECENT INDUSTRY ACTIVITY
Takeda Resubmits 2 NDAs for Alogliptin in the US
Astellas to Divest DPP-4 Inhibitor Patents to Royal Pharma
Sun Pharmaceutical Enters into a Partnership Deal with Merck
Boehringer Ingelheim and Lilly Enter into Licensing Agreement
Kowa Initiates Phase-II Trial of Anagliptin
Phenomix Shuts Shop in the Wake of Breakdown of Dutogliptin Deal
Forest Labs Opts Out of Anti-Diabetic Drug Deal with Phenomix
Double-Crane and LG Life Sciences Enter Agreement for Sale of LC-15-0444
Bristol-Myers Squibb Enters into Collaboration with AstraZeneca
Takeda Terminates Development of TAK 100
Merck Obtains Positive Opinion from CHMP for Use of sitagliptin with Insulin
Merck and Cigna Ink “Performance-Based Contract”
Novartis Terminates Eucreas Development Program in the US
Chiesi and Phenomix Ink Development and Commercialization Deal for Dutogliptin
America Stem Cell and Dara Biosciences Sign Material Transfer Agreement
Egis Acquires Marketing License for Januvia in Hungary
Novartis Joins Hands with USV to Market Galvus in India
Merck and Almirall Enter into an Agreement to Commercialize Tesavell in Spain
Forest Teams Up with Phenomix for Developing DPP-IV Inhibitor – Dutogliptin
Sanwa Kagaku and Kowa Ink Deal to Co-develop DPP-4 inhibitor - SK-0403
Novartis’ Diabetes Drug Galvus Faces Delay in FDA Approval
9.FOCUS ON SELECT GLOBAL PLAYERS
Arisaph Pharmaceuticals, Inc. (US)
AstraZeneca Plc. (UK)
Boehringer Ingelheim GmbH (Germany)
Bristol-Myers Squibb (US)
Eli Lilly And Company (US)
Merck & Co, Inc. (US)
Mitsubishi Tanabe Pharma Corporation (Japan)
Novartis AG (Switzerland)
Takeda Pharmaceutical Company Limited (Japan)
10.GLOBAL MARKET PERSPECTIVE
Table 13: World Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 14: World 10-Year Perspective for DPP-IV Inhibitors by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
Table 15: World Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Drug Class – Sitagliptin, Vildagliptin, Saxagliptin and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 16: World 10-Year Perspective for DPP-IV Inhibitors by Drug Class – Percentage Breakdown of Dollar Sales for Sitagliptin, Vildagliptin, Saxagliptin and Others Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
11.THE UNITED STATES
A. Market Analysis
Current & Future Analysis
Diabetes Pandemic in the US
Non-Insulin Products Dominate the Diabetes Therapeutics Market
Table 17: US Non-Insulin Anti-Diabetic Market by Drug Class (2010 & 2017): Percentage Breakdown of Revenues for Metformin, DPP-4 Inhibitors, Sulfonylureas, Thiazolidinediones, GLP-1 Analogues, and Others (includes corresponding Graph/Chart)
DPP-IV Inhibitors All Set to Gain Market Share in Oral Anti-Diabetics
Januvia Leads the Way, Will Remain the Top Drug Through 2017
Minimal Differentiation Affects Sales of Onglyza
Table 18: US Total Prescriptions of Januvia and Onglyza Analyzed in Terms of Total Prescriptions Since Launch in Thousands (includes corresponding Graph/Chart)
FDA’s Issue of Safety Alert on Januvia and Janumet
Increasing Scrutiny of NDAs Bodes Tough Time for New Drugs
Product Approvals/Launches
Strategic Corporate Developments
Focus on Select Key Players
B. Market Analytics
Table 19: The US Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
12.CANADA
Market Analysis
Table 20: Canadian Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
13.JAPAN
A. Market Analysis
Current & Future Analysis
Competition in Japanese DPP-IV Inhibitor Market Heats Up
Product Approvals/Launches
Strategic Corporate Developments
Focus on Select Key Players
B. Market Analytics
Table 21: Japanese Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
14.EUROPE
A. Market Analysis
Current & Future Analysis
Treatment Strategies of Type-2 Diabetes in Europe
Product Approvals/Launches
Strategic Corporate Developments
B. Market Analytics
Table 22: European Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Geographic Region – France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 23: European 10-Year Perspective for DPP-IV Inhibitors by Geographic Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
14A.FRANCE
Market Analysis
Table 24: French Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
14B.GERMANY
A. Market Analysis
Boehringer Ingelheim GmbH – A Key Player
B. Market Analytics
Table 25: German Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
14C.ITALY
Market Analysis
Table 26: Italian Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
14D.THE UNITED KINGDOM
A. Market Analysis
Current & Future Analysis
Blacklisting of Drugs in UK Raises Concerns
AstraZeneca Plc. – A Key Player
B. Market Analytics
Table 27: The UK Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
14E.REST OF EUROPE
A. Market Analysis
Novartis AG – A Major Player
B. Market Analytics
Table 28: Rest of European Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
15.ASIA-PACIFIC
A. Market Analysis
Current & Future Analysis
Overview of Select Markets in the Region
India
DPP-4 Inhibitor to Garner Increasing Share in Indian Diabetes Drugs Market
Strong Growth Ahead for Anti-Diabetes Products in India
First-to-Market Advantage and Unique Strategy Keep Januvia Ahead of Competition
China
China Lags in DPP-4 Inhibitors Market, Bodes Robust Growth Ahead
Australia
Rising Incidence of Diabetes
Diabetes Market – A Window of Opportunity Restricted by PBS
Korea
Januvia Franchise Reigns in Korean DPP- IV Market
Product Approvals/Launches
Strategic Corporate Developments
B. Market Analytics
Table 29: Asia-Pacific Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
16.REST OF WORLD
A. Market Analysis
Current & Future Analysis
A Sneak-Peak at Brazilian Diabetes Market
B. Market Analytics
Table 30: Rest of World Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Competitive Landscape
Total Companies Profiled: 31 (including Divisions/Subsidiaries - 33)
Region/CountryPlayers
The United States
Japan
Europe
Germany
The United Kingdom
Italy
Spain
Rest of Europe
Asia-Pacific (Excluding Japan)
Skip to top